We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » HHS 2005 PRIORITIES TO INCLUDE CLINICAL STUDIES
HHS 2005 PRIORITIES TO INCLUDE CLINICAL STUDIES
October 22, 2004
Determining the extent to which the FDA monitors postmarketing study commitments and evaluating the pharmaceutical industry's compliance with requirements that submit data on clinical trials involving serious conditions are among the investigations HHS' Office of Inspector General (OIG) plans to undertake in fiscal 2005.